AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
January 14, 2020 16:01 ET | Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Reports and Data.jpeg-01
Neurostimulation Devices Market To Reach USD 12.7 Billion By 2026 | Reports And Data
January 08, 2020 09:53 ET | Reports and Data
New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Neurostimulation Devices market was valued at USD 4.98 Billion in 2018 and is expected...
Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia
December 30, 2019 02:00 ET | Orion Oyj
ORION CORPORATION PRESS RELEASE 30 DECEMBER 2019 at 9.00 EET                        Orion Corporation (“Orion”) and Lotus Pharmaceutical Co., Ltd. (“Lotus”) have made a marketing and distribution...
Lotus Orionin Stalevo®- ja Comtan®-lääkkeiden jakelijaksi osassa Aasiaa
December 30, 2019 02:00 ET | Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 30.12.2019 klo 09.00                 Orion Oyj (”Orion”) ja Lotus Pharmaceutical Co., Ltd. (”Lotus”) ovat tehneet markkinointi- ja jakelusopimuksen koskien Orionin...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
December 12, 2019 07:07 ET | Aptinyx Inc.
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
December 05, 2019 06:58 ET | Aptinyx Inc.
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned
December 02, 2019 13:00 ET | Herantis Pharma Oyj
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned Herantis Pharma Plc Company release 2 December 2019 at 8:00 pm THE INFORMATION CONTAINED IN...
Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti
December 02, 2019 13:00 ET | Herantis Pharma Oyj
Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti Herantis Pharma Oyj Yhtiötiedote 2.12.2019 kello 20:00 TÄMÄN TIEDOTTEEN SISÄLTÄMÄ TIETO EI...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at Upcoming Investor Conferences
November 14, 2019 07:57 ET | Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.
November 13, 2019 08:00 ET | Curium
St. Louis MO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Curium announced today that it intends to submit an abbreviated new drug application for a generic version of DaTscanTM (Ioflupane I 123 Injection) in...